Wide Ranks

BCDA

BioCardia, Inc.

2.35

Top Statistics
Market Cap 10 M Forward PE -1.93 Revenue Growth -93.00 %
Current Ratio 0.39 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -0.4690 Enterprise / Revenue 9.34 Price To Sales Trailing12 Months 25.17
Profitability
Profit Margins 0.00 % Operating Margins -54966.67 %
Balance Sheet
Total Cash 1 M Total Cash Per Share 0.6690 Total Debt 1 M
Total Debt To Equity Current Ratio 0.39 Book Value Per Share -1.02
All Measures
Short Ratio 141.00 % Message Board Id finmb_9776743 Fax 650 631 3731
Shares Short Prior Month 132100 City Sunnyvale Uuid 8b80cfe5-bb21-30a0-847c-0f215539e9b5
Previous Close 2.28 First Trade Date Epoch Utc 847 M Book Value -1.02
Beta 1.27 Total Debt 1 M Volume 43940
Last Split Date 1 B Fifty Two Week Low 1.84 Total Cash Per Share 0.6690
Total Revenue 428000 Shares Short Previous Month Date 1 B Target Median Price 25.00
Max Age 86400 Recommendation Mean 2.00 Sand P52 Week Change 0.3133
Operating Margins -54966.67 % Target Mean Price 25.00 Net Income To Common -8559000
Short Percent Of Float 0.0265 Implied Shares Outstanding 4 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 51140 Average Volume10days 51140
Total Cash 1 M Next Fiscal Year End 1 B Revenue Per Share 0.2640
Held Percent Insiders 0.1407 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 2.28 Target Low Price 25.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 2.49 Open 2.39
Free Cashflow -3851750 State CA Dividend Yield 0.00 %
Return On Assets -1.16 Time Zone Short Name EST Trailing Eps -4.03
Day Low 2.28 Address1 320 Soquel Way Shares Outstanding 4 M
Price Hint 4 Target High Price 25.00 Website https://www.biocardia.com
52 Week Change -0.7473 Average Volume 792175 Forward Eps -1.27
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 35.20 %
Last Split Factor 1:15 Regular Market Day High 2.41 Is_sp_500 False
Profit Margins 0.00 % Fifty Two Week High 10.80 Day High 2.41
Shares Short 86275 Regular Market Open 2.39 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 9.34 Revenue Growth -93.00 %
Shares Percent Shares Out 0.0246 Operating Cashflow -7105000 Currency USD
Time Zone Full Name America/New_York Market Cap 10 M Is_nasdaq_100 False
Zip 94085 Quote Type EQUITY Industry Biotechnology
Long Name BioCardia, Inc. Regular Market Day Low 2.28 Held Percent Institutions 0.0221
Current Price 2.35 Enterprise To Ebitda -0.4690 Financial Currency USD
Current Ratio 0.39 Industry Disp Biotechnology Number Of Analyst Opinions 1
Country United States Float Shares 1 M Two Hundred Day Average 4.02
Ir Website http://quotes.nasdaq-amex.com/Quote.dll?page=multi&mode=stock&symbol=NAMC Enterprise Value 3 M Price To Sales Trailing12 Months 25.17
Forward PE -1.93 Regular Market Volume 43940 Ebitda -8529000
Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States.

Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.

The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome.

In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths.

The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction.

BioCardia, Inc. is based in Sunnyvale, California.